HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aesthetic Medicine

1,465.971

+25.2121.75%

Number of Gainers:4

Number of Losers:6

Number of Flat:3

PE:- -

High:1,473.594

Open:1,441.486

Low:1,412.502

Close:1,440.759

Volume:128.81M

Turnover:2.14B

Market Cap:240.51B

Float Cap:177.31B

Loading ...

Raily Aesthetic Medicine International Holdings H1 Gross Profit RMB 29.1 Million

THOMSON REUTERS

Over 2.8 Billion RMB! Fosun Pharma Subsidiary Delivers Outstanding First-Half Performance

3SBio's Profit Jumps 25% in H1

MT Newswires Live

BRIEF-3Sbio Posts H1 Gross Margin Of 85.3%

FOSUN PHARMA (02196): Fosun Pharma Industry Signs License Agreement with Akeso

3SBio H1 Gross Margin 85.3%

THOMSON REUTERS

3SBio H1 Ebitda RMB 1,832.5 Million

THOMSON REUTERS

3SBio - Hy Revenue RMB4,355.5 Mln

THOMSON REUTERS

SIHUAN PHARM (00460): Chen Yanling to be Appointed as Member of Nomination Committee

Sihuan Pharmaceutical Announces Ms. Chen Yanling's Appointment to Nomination Committee

BRIEF-Sihuan Pharmaceutical Posts H1 Gross Profit RMB757.3 Million

Sihuan Pharmaceutical Returns to Profitability in H1; Shares Up 4%

MT Newswires Live

SIHUAN PHARM (00460) Reports Interim Results with Shareholder Profit of RMB103 Million, Turning from Loss to Profit Year-on-Year

Sihuan Pharmaceutical Holdings Group Ltd. Announces Interim Cash Dividend of RMB 0.0099 Per Share

Sihuan Pharma - Resolved to Declare an Interim Cash Dividend of RMB0.99 Cents per Share

THOMSON REUTERS

Sihuan Pharmaceutical Holdings Group H1 Pretax Profit RMB 156.9 Million

THOMSON REUTERS

Sihuan Pharmaceutical Holdings Group H1 Operating Profit RMB 264.4 Million

THOMSON REUTERS

Sihuan Pharmaceutical Holdings Group H1 Gross Margin 66.1%

THOMSON REUTERS

ANGELALIGN Surges Over 7% in Morning Session as Overseas Business Expansion Drives H1 Revenue Above Expectations

Modern Dental (03600) Reports Interim Results with Shareholder Attributable Profit of HK$285 Million, Up 32.52% Year-on-Year

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1593/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"Aesthetic Medicine","latestPrice":1465.9714,"timestamp":1757405290965,"preClose":1440.759,"halted":0,"volume":128805171,"delay":0,"changeRate":0.017499,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":25.212402,"latestTime":"09-09 16:00:00","open":1441.4856,"high":1473.5939,"low":1412.5018,"amount":2139217392,"amplitude":0.042403,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1757467800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1757381400000,1757390400000],[1757394000000,1757404800000]],"pbRate":2.085437,"peRate":29.311372,"turnoverRate":0.006228,"increases":4,"decrements":6,"flats":3,"marketCap":240505319816,"floatMarketCap":177312741768},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":1473.5939,"amplitude":0.042403,"preClose":1440.759,"low":1412.5018,"pbRate":"2.085437","latestPrice":1465.9714,"volume":128805171,"delay":0,"open":1441.4856,"prevYearClose":571.87146,"prevWeekClose":1420.862,"prevMonthClose":1253.623,"prevQuarterClose":1037.486,"fiveDayClose":1314.432,"twentyDayClose":1260.192,"sixtyDayClose":1033.634,"secType":"PLATE","market":"HK","turnoverRate":0.006228,"peRate":29.311372,"marketCap":240505319816,"floatMarketCap":177312741768,"timestamp":1757405290965,"nameCN":"Aesthetic Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":4,"down":6,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2563155028","title":"Raily Aesthetic Medicine International Holdings H1 Gross Profit RMB 29.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2563155028","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563155028?lang=en_us&edition=fundamental","pubTime":"2025-08-29 20:17","pubTimestamp":1756469864,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nPLX4AE6DD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02135","BK1593","BK1209"],"gpt_icon":0},{"id":"1197300065","title":"Over 2.8 Billion RMB! Fosun Pharma Subsidiary Delivers Outstanding First-Half Performance","url":"https://stock-news.laohu8.com/highlight/detail?id=1197300065","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197300065?lang=en_us&edition=fundamental","pubTime":"2025-08-29 19:10","pubTimestamp":1756465850,"startTime":"0","endTime":"0","summary":"Recently, Henlius, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co.,Ltd., released its 2025 interim results. The company achieved revenue of 2.8195 billion RMB in the first half of 2025,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","02196","BK0196","BK1515","BK0175","BK0096","600196","BK0188","BK0028","BK0012","BK1191","BK0239","BK0187","BK1593","BK0060"],"gpt_icon":0},{"id":"2563445060","title":"3SBio's Profit Jumps 25% in H1","url":"https://stock-news.laohu8.com/highlight/detail?id=2563445060","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563445060?lang=en_us&edition=fundamental","pubTime":"2025-08-29 18:53","pubTimestamp":1756464817,"startTime":"0","endTime":"0","summary":"3SBio  saw a 25% rise in attributable profit in the first half of 2025 to 1.36 billion yuan from 1.09 billion yuan in the year-ago period, a Friday filing with the Hong Kong bourse said.Earnings per share for the biopharmaceutical company rose to 0.56 yuan from 0.45 yuan in the corresponding period of the previous year.Revenue for the half year fell 0.8% to 4.36 billion yuan from 4.39 billion yuan a year prior.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1583","01530","BK1593"],"gpt_icon":1},{"id":"2563049012","title":"BRIEF-3Sbio Posts H1 Gross Margin Of 85.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563049012","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563049012?lang=en_us&edition=fundamental","pubTime":"2025-08-29 18:25","pubTimestamp":1756463149,"startTime":"0","endTime":"0","summary":"BRIEF-3Sbio Posts H1 Gross Margin Of 85.3%Aug 29  - 3SBio Inc 1530.HK:H1 GROSS MARGIN 85.3%H1 ADJUSTED EBITDA RMB 1,610.1 MILLIONH1 EBITDA RMB 1,832.5 MILLIONHY NET PROFIT ATTRIBUTABLE RMB1,358.2 MILLIONHY REVENUE RMB4,355.5 MILLIONFurther company coverage: 1530.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nPLXC222E9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01530","BK1583","BK1593"],"gpt_icon":0},{"id":"1110863030","title":"FOSUN PHARMA (02196): Fosun Pharma Industry Signs License Agreement with Akeso","url":"https://stock-news.laohu8.com/highlight/detail?id=1110863030","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110863030?lang=en_us&edition=fundamental","pubTime":"2025-08-29 18:18","pubTimestamp":1756462716,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) announced that on August 29, 2025, the company's controlling subsidiary Fosun Pharma Industry entered into a License Agreement with Akeso. Under the agreement, Fosun Pharma...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK1515","BK0239","BK0060","BK0096","BK1593","BK0188","02196","BK0028","BK0196","BK1191","BK0183","BK0012","600196","BK0187"],"gpt_icon":0},{"id":"2563604650","title":"3SBio H1 Gross Margin 85.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563604650","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563604650?lang=en_us&edition=fundamental","pubTime":"2025-08-29 18:00","pubTimestamp":1756461656,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nPLXC222E9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","01530","BK1593","BK1161"],"gpt_icon":0},{"id":"2563570046","title":"3SBio H1 Ebitda RMB 1,832.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2563570046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563570046?lang=en_us&edition=fundamental","pubTime":"2025-08-29 18:00","pubTimestamp":1756461656,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nPLXC222E9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01530","BK1593","BK1583","BK1161"],"gpt_icon":0},{"id":"2563046453","title":"3SBio -  Hy Revenue RMB4,355.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2563046453","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563046453?lang=en_us&edition=fundamental","pubTime":"2025-08-29 18:00","pubTimestamp":1756461656,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nPLXC222E9:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1593","BK1161","01530"],"gpt_icon":0},{"id":"1175605827","title":"SIHUAN PHARM (00460): Chen Yanling to be Appointed as Member of Nomination Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=1175605827","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175605827?lang=en_us&edition=fundamental","pubTime":"2025-08-29 17:40","pubTimestamp":1756460416,"startTime":"0","endTime":"0","summary":"SIHUAN PHARM (00460) announced that Ms. Chen Yanling, the company's current executive director, will be appointed as a member of the company's nomination committee, effective from September 1, 2025.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1515","BK1593","BK1191","BK1600"],"gpt_icon":0},{"id":"2563048606","title":"Sihuan Pharmaceutical Announces Ms. Chen Yanling's Appointment to Nomination Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2563048606","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563048606?lang=en_us&edition=fundamental","pubTime":"2025-08-29 17:17","pubTimestamp":1756459054,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group Ltd. announced a change in the composition of its Nomination Committee. Ms. Chen Yanling, an existing executive director, will be appointed as a member of the committee, effective September 1, 2025. The Nomination Committee will continue to have a majority of independent non-executive directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL4V8SpS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1593","BK1600","00460","BK1191"],"gpt_icon":0},{"id":"2563901238","title":"BRIEF-Sihuan Pharmaceutical Posts H1 Gross Profit RMB757.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2563901238","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563901238?lang=en_us&edition=fundamental","pubTime":"2025-08-29 16:12","pubTimestamp":1756455151,"startTime":"0","endTime":"0","summary":"BRIEF-Sihuan Pharmaceutical Posts H1 Gross Profit RMB757.3 MillionAug 29  - Sihuan Pharmaceutical Holdings Group Ltd 0460.HK:H1 GROSS PROFIT RMB 757.3 MILLIONH1 GROSS MARGIN 66.1%H1 PRETAX PROFIT RMB 156.9 MILLIONH1 REVENUE RMB 1,146.2 MILLIONH1 OPERATING PROFIT RMB 264.4 MILLIONRESOLVED TO DECLARE AN INTERIM CASH DIVIDEND OF RMB0.99 CENTS PER SHAREFurther company coverage: 0460.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nPLXA63585:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1515","BK1593","BK1191","BK1600"],"gpt_icon":0},{"id":"2563018002","title":"Sihuan Pharmaceutical Returns to Profitability in H1; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563018002","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563018002?lang=en_us&edition=fundamental","pubTime":"2025-08-29 13:22","pubTimestamp":1756444960,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical  reported 102.6 million yuan in attributable profit for the first half of 2025, reversing the loss of 33.4 million yuan a year earlier, according to a Hong Kong bourse filing Friday.Earnings per share were 0.0111 yuan, compared with a loss of 0.0036 yuan in the prior year.Revenue increased 21% year-on-year to 1.15 billion yuan, figures showed.The company declared a dividend of HK$0.0109 per share, payable Oct. 10 to shareholders of record on Oct. 2.Shares of the pharma research company gained over 4% in midday trade Friday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1593","00460","BK1600","BK1515","BK1191"],"gpt_icon":0},{"id":"1153476592","title":"SIHUAN PHARM (00460) Reports Interim Results with Shareholder Profit of RMB103 Million, Turning from Loss to Profit Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1153476592","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153476592?lang=en_us&edition=fundamental","pubTime":"2025-08-29 12:30","pubTimestamp":1756441845,"startTime":"0","endTime":"0","summary":"SIHUAN PHARM (00460) announced its interim results for 2025, with revenue reaching RMB1.146 billion (same currency hereinafter), representing a year-on-year increase of 20.69%. Profit attributable to...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1600","BK1593","BK1515","BK1191"],"gpt_icon":0},{"id":"2563909031","title":"Sihuan Pharmaceutical Holdings Group Ltd. Announces Interim Cash Dividend of RMB 0.0099 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2563909031","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563909031?lang=en_us&edition=fundamental","pubTime":"2025-08-29 12:20","pubTimestamp":1756441241,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group Ltd. has announced an interim cash dividend of RMB 0.0099 per share for the six months ended 30 June 2025. This ordinary dividend, relating to the financial year ending 31 December 2025, will be paid on 10 October 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL5cQc9R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1593","BK1515","00460","BK1600"],"gpt_icon":0},{"id":"2563970670","title":"Sihuan Pharma -  Resolved to Declare an Interim Cash Dividend of RMB0.99 Cents per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2563970670","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563970670?lang=en_us&edition=fundamental","pubTime":"2025-08-29 12:17","pubTimestamp":1756441035,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nPLXA63585:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1515","BK1593","BK1600","00460"],"gpt_icon":0},{"id":"2563909709","title":"Sihuan Pharmaceutical Holdings Group H1 Pretax Profit RMB 156.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2563909709","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563909709?lang=en_us&edition=fundamental","pubTime":"2025-08-29 12:17","pubTimestamp":1756441035,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nPLXA63585:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","BK1600","BK1515","BK1191","00460"],"gpt_icon":0},{"id":"2563097098","title":"Sihuan Pharmaceutical Holdings Group H1 Operating Profit RMB 264.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2563097098","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563097098?lang=en_us&edition=fundamental","pubTime":"2025-08-29 12:17","pubTimestamp":1756441035,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nPLXA63585:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1593","00460","BK1600","BK1515"],"gpt_icon":0},{"id":"2563096097","title":"Sihuan Pharmaceutical Holdings Group H1 Gross Margin 66.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563096097","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563096097?lang=en_us&edition=fundamental","pubTime":"2025-08-29 12:17","pubTimestamp":1756441035,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nPLXA63585:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","00460","BK1600","BK1593","BK1515"],"gpt_icon":0},{"id":"1161746437","title":"ANGELALIGN Surges Over 7% in Morning Session as Overseas Business Expansion Drives H1 Revenue Above Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=1161746437","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161746437?lang=en_us&edition=fundamental","pubTime":"2025-08-29 12:11","pubTimestamp":1756440705,"startTime":"0","endTime":"0","summary":"ANGELALIGN (06699) rose more than 8% during trading, and as of press time, the stock price was up 7.24%, trading at HK$74.10 with a turnover of HK$142 million. ANGELALIGN announced its interim...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1587","BK1583","06699","BK1593"],"gpt_icon":0},{"id":"1177701158","title":"Modern Dental (03600) Reports Interim Results with Shareholder Attributable Profit of HK$285 Million, Up 32.52% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1177701158","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177701158?lang=en_us&edition=fundamental","pubTime":"2025-08-28 23:36","pubTimestamp":1756395379,"startTime":"0","endTime":"0","summary":"Modern Dental (03600) announced its interim results for the six months ended June 30, 2025. The group achieved revenue of HK$1.835 billion, representing a 7.81% year-on-year increase. Profit...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1593","03600","BK1583"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":83,"code":"91000000","status":"200"}]}}